Manteia received a round of financing of RMB 100 million, and Danlu and Deyi jointly invested
The investment community (ID: pedaily2012) reported on December 29 that manteia technology, an adaptive radiotherapy system R & D company, has completed a round of financing of RMB 100 million, which is jointly invested by Danlu capital and Deyi capital.
Manteia is a radiotherapy technology R & D company with algorithm innovation as the core. Through the joint architecture of AI and traditional algorithms, manteia positions "algorithm innovation" as "optimization and combination innovation", which is not limited to "creation". The algorithm simulates clinical logic to solve clinical problems and achieve accuracy, efficiency and automation.
Manteia products mainly include adaptive radiation therapy (Art) system and common product modules, algorithm component libraries and plug-ins for radiotherapy. Provide more efficient and accurate intelligent planning tools (automatic drawing, automatic planning, biological optimization, etc.) and systems for clinical treatment.
The team's adaptive radiotherapy research group was first established in 2011 and has nearly a decade of technical experience in the field of adaptive radiotherapy. At present, it has independent laboratories and joint laboratories, 30 global joint R & D units, more than 80 research projects and 20 + international joint projects.
Within one year, manteia has successively obtained the product registration certification of four mainstream markets: FDA, nmpa in China, CE in Europe and KFDA in Korea, and has become the first radiotherapy company in China with a pass to enter the markets of China, the United States, Europe and Korea. The company has also passed ISO13485, mdsap and other international quality system certification, paving the way for entering the global radiotherapy market. At present, it has entered more than 300 head hospitals in the world, including the United States, Canada, South Korea and other countries, serving thousands of patients every day.
This article is original for the investment circles. The webpage reprint must indicate the source investment community (WeChat public number ID:PEdaily2012) and the author's name in the first official account. WeChat is required to contact the authorized authorities in the original comment area of WeChat. If the company fails to comply, the investment community will be held liable for it.